Form 8-K - Current report:
SEC Accession No. 0001193125-25-137094
Filing Date
2025-06-06
Accepted
2025-06-06 16:23:56
Documents
14
Period of Report
2025-06-06
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d941196d8k.htm   iXBRL 8-K 28808
2 EX-99.1 d941196dex991.htm EX-99.1 66899
6 GRAPHIC g941196g56z49.jpg GRAPHIC 8319
  Complete submission text file 0001193125-25-137094.txt   238105

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA phat-20250606.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE phat-20250606_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE phat-20250606_pre.xml EX-101.PRE 11273
16 EXTRACTED XBRL INSTANCE DOCUMENT d941196d8k_htm.xml XML 3646
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Filer) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39094 | Film No.: 251031058
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)